

YOU'RE INVITED



The First and Only BTKi Offering the Choice of All-Oral Fixed-Duration^a and Continuous^b Regimens in 1L CLL



Jennifer Greenfield
MSN, APRN, NP-C, AOCNP
Robert H Lurie Cancer Center of Northwestern



May 14th, 2026
6:15 PM to 7:30 PM Central Standard Time



Bleu Restaurant and Lounge
2200 Dickinson Road
De Pere, WI 54115

RSVP

Kathryn Limoni
(920) 819-3218 or kathryn.limoni@astrazeneca.com
By 5/8/2026

^aDesigned to be completed in fourteen 28-day cycles (2 cycles of CALQUENCE monotherapy followed by 12 cycles of CALQUENCE + venetoclax, starting venetoclax using a 5-week ramp-up per dose schedule), unless disease progression or unacceptable toxicity warrants earlier discontinuation.

^bCALQUENCE monotherapy given until disease progression or unacceptable toxicity.

INDICATION AND USAGE

CALQUENCE is a Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

SELECT SAFETY INFORMATION

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions ($\geq 30\%$) are upper respiratory tract infection, diarrhea, headache, and musculoskeletal pain. The most common Grade 3 or 4 laboratory abnormalities ($\geq 10\%$) are absolute neutrophil count decreased, uric acid increased, absolute lymphocyte count decreased, and platelets decreased.

Please see accompanying full Prescribing Information, including Patient Information.

Reference: CALQUENCE[®] (acalabrutinib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.

PhRMA guidance: This event is conducted in accordance with the PhRMA Code on Interaction with Healthcare Professionals and is limited to healthcare professionals with an educational need for the information being presented. Attendees are expected to stay for the entire duration of the presentation. Repeat attendance at a Speaker Program on the same or substantially the same topic is generally not appropriate unless the attendee has a legitimate educational need to attend. Attendance by guests or spouses is generally not appropriate. AstraZeneca will not pay for or provide alcohol in connection with our Speaker Programs.

State and Federal Laws: Certain states and federal agencies have defined the maximum fair market value allowable for modest meals given to healthcare professionals or prohibited the receipt of meals at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are impacted by those restrictions, we respectfully request that you not partake in the meal offered by AstraZeneca at the event. Please ask the AstraZeneca representative at the event for information about purchasing food at the event.

Disclosure by AstraZeneca: Subject to federal and state regulations, AstraZeneca will disclose information related to meals provided to attendees, which will be made public. To ensure accurate transparency reporting of meals, AstraZeneca requires program attendees to sign in upon arrival and indicate if a meal was accepted.

This program is intended for US healthcare professionals only.

AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. AstraZeneca fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guests of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a Federal, State, or institution employee, you may be subject to laws, regulations, or rules that prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions. AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits.

AstraZeneca
1800 Concord Pike, PO Box 15437, Wilmington, DE 19850-5437



CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2026 AstraZeneca. All rights reserved. US-105650 3/26